Minerva Neurosciences | Passivo Circulante





Passivo Circulante Alterar Data
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Adma Biologics USD 56.49M 18.45M 2025-09
ALKERMES USD 543.44M 69.08M 2025-12
Alterity Therapeutics Limited AUD 4.38M 849.82K 2023-06
AstraZeneca USD 30.62B 3.44B 2025-12
BioCryst Pharmaceuticals USD 190.24M 13.08M 2025-09
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Cipla INR 62.97B 8.13B 2025-09
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 20.28M 300K 2025-09
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Esperion Therapeutics USD 359.03M 60.24M 2025-09
GlaxoSmithKline GBP 21.39B 57M 2025-12
Grifols EUR 2.53B 182.67M 2025-09
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
J&J USD 54.13B 3.26B 2025-12
Merck USD 28.63B 2.59B 2025-09
Minerva Neurosciences USD 2.67M 143K 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 32B 286M 2025-09
Novavax USD 429.87M 40.73M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 28.35B 3.76B 2025-12
Takeda JPY 2.61T 470.53B 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12


Minerva Neurosciences Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2026.